Previous 10 | Next 10 |
2024-01-20 03:41:05 ET Summary PepGen is using exon skipping therapies to address muscular dystrophy conditions, specifically Duchenne muscular dystrophy (DMD) and Myotonic dystrophy type 1 (DM1). They are developing PGN-EDO51 and PGN-EDODM1. The market sizes for these therapi...
- Preliminary data from the 5 mg/kg PGN-EDO51 dose level in the CONNECT1-EDO51 Phase 2 trial are expected mid-2024: including initial safety, exon 51 skipping and dystrophin protein production data - - Phase 1 results following a single dose of 10 mg/kg of PGN-EDO51 in healthy volunteer...
- Safety, transcript splicing correction and clinical outcome measures data at 5 mg/kg PGN-EDODM1 dose level in patients from FREEDOM-DM1 clinical trial expected in 2024 - - Clearance of Clinical Trial Application (CTA) by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) ...
BOSTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of...
PepGen Inc. (PEPG) is expected to report $-0.88 for Q3 2023
2023-11-08 08:59:41 ET More on PepGen PepGen: Unearthing A Potential Trailblazer With An Attractive Risk-Reward FDA lifts clinical hold on US Phase 1 study for DM1 drug candidate Seeking Alpha’s Quant Rating on PepGen Historical earnings data for PepGe...
- Continuing to open CONNECT1-EDO51 trial sites in Canada - - Opening of FREEDOM-DM1 trial sites underway in the U.S. and Canada - - Ended third quarter 2023 with cash and cash equivalents of $129.5 million; cash runway expected into 2025 - BOSTON, Nov. 08, 2023 (G...
2023-10-12 13:54:07 ET More on PepGen PepGen: Unearthing A Potential Trailblazer With An Attractive Risk-Reward PepGen GAAP EPS of -$0.82 Seeking Alpha’s Quant Rating on PepGen Historical earnings data for PepGen Financial information for PepGe...
– Lifting of FDA hold allows FREEDOM-DM1 study to launch in the U.S. with target dose levels of 5 mg/kg, 10 mg/kg and 20 mg/kg – – Safety, transcript splicing and clinical outcome measures data at 5 mg/kg PGN-EDODM1 dose level in patients from FREEDOM-DM1 clinical stu...
2023-10-05 06:24:08 ET Summary PepGen is a small-cap healthcare company focused on developing therapies for genetic disorders, particularly Duchenne muscular dystrophy. The company's Enhanced Delivery Oligonucleotide platform shows promising results in increasing the delivery and ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-06 15:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the expansion of its executive team with the appointments of...
Michelle Mellion, M.D., promoted to Chief Medical Officer Hayley Parker, Ph.D., promoted to Senior Vice President, Global Regulatory Affairs PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of t...